Recent Advances with Monoclonal Antibody Drug Targeting for the Treatment of Human Cancer

Bioconjugate Chemistry

Volumn 1, Issue 1, 1990, Pages 13-23

  Koppel, Gary A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; MONOCLONAL ANTIBODY; PRODRUG;

ANIMAL; CELL LINE; HUMAN; HYBRIDOMA; IMMUNOLOGY; MOUSE; NEOPLASM; NUDE MOUSE; REVIEW; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG CARRIERS; HUMANS; HYBRIDOMAS; MICE; MICE, NUDE; NEOPLASMS; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0025200067     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc00001a002     Document Type: Article

References (108)

1. This review was presented as a lecture at the Dedicatory Symposia for the Journal of Bioconjugates at the American Chemical Society Meeting, Dallas, Texas, April 11, 1989.
2. The concept was presented as part of a lecture at the dedication of the Georg-Speyer-Haus, September 6, 1906; see: (1962) Readings in Pharmacology (Louis Shuster, Ed.) Little, Brown, and Company, Boston, MA.
3. Benacerraf, B. and Germain, R. N. (1978) The immune response genes of the major histocompatibility complex. Immunol. Rev. 38, 70–119.
4. Benacerraf, B. (1982) Genetics and regulation of the immune response. Natl. Cancer Inst. Monogr. 60, 171–173.
5. Benecerraf, B. and Rock, K. L. (1984) The interaction between class II MHC molecules and antigens as a basis for Ir gene specificity. Ann. Immunol. (Paris) 135C (3), 386–389.
6. McDevitt, H. O., Deak, B. D., Shreffler, D. C., Klein, J., Stimpfling, J. H., and Snell, G. D. (1972) Genetic control of the immune response. Mapping of the Ir-1 locus. J. Exp. Med. 135 (6), 1259–1278.
7. Snell, G. D. (1976) Recognition structures determined by the H-2 complex. Transplant. Proc. 8 (2), 147–156.
8. Snell, G. D. (1978) T cells, T cells recognition structures, and the major histocompatibility complex. Immunol. Rev. 38, 3–69.
9. Snell, G. D. (1979) Recent advances in histocompatibility immunogenetics. Adv. Genet. 20, 291–355.
10. Snell, G. D. (1980) The major histocompatibility complex: Its evolution and involvement in cellular immunity. Harvey Lect. 74, 49–80.
11. Snell, G. D. (1981) Studies in histocompatibility. Science 213 (4504), 172–178.
12. Snell, G. D. (1981) The future of immunogenetics. Prog. Clin. Biol. Res. 45, 241–272.
13. Kohler, G., Howe, S. C., and Milstein, C. (1976) Fusion between immunoglobulin secreting and non-secreting myeloma cell lines. Eur. J. Immunol. 6, 292–295.
14. Kohler, G. (1985) Derivation and diversification of monoclonal antibodies. Nobel lecture. Biosci. Rep. 5 (7), 533–549.
15. Kohler, G. (1986) Derivation and diversification of monoclonal antibodies. Science 233 (4770), 1281–1286.
16. Tonegawa, S. (1988) Nobel lecture in physiology or medicine-1987. Somatic generation of immune diversity. In Vitro Cell Dev. Biol. 24 (4), 253–265.
17. Tonegawa, S. (1979–1980) Somatic recombination and mosaic structure of immunoglobulin genes. Harvey Lect. 75, 61–83.
18. Tonegawa, S. (1988) Somatic generation of immune diversity. Biosci. Rep. 8 (1), 3–26.
19. Hood, L. (1988) Biotechnology and medicine of the future. J. Am. Med. Assoc. 259 (12), 1837–1844.
20. Perlmutter, R. M., Berson, B., Griffin, J. A., and Hood, L. (1985) Diversity in the germline antibody repertoire. Molecular evolution of the T15 VN gene family. J. Exp. Med. 162 (6), 1998–2016.
21. Perlmutter, R. M., Crews, S. T., Douglas, R., Sorensen, G., Johnson, N., Nivera, N., Gear-hart, P. J., and Hood, L. (1984) The generation of diversity in phosphorylcholine-binding antibodies. Adv. Immunol. 35, 1–37.
22. Marchitto, K. S., Kindsvogel, W. R., Beaumier, P. L., Fine, S. K., Gilbert, T., Levin, S. D., Woodhouse, C. S., and Morgan, A. C., Jr. (1989) Characterization of a human-mouse chimeric antibody reactive with a human melanoma associated antigen. Prog. Clin. Biol. Res. 288, 101–105.
23. Colcher, D., Milenic, D., Roselli, M., Raubitschek, A., Yarran-ton, G., King, D., Adair, J., Whittle, N., Bodmer, M., and Schlom, J. (1989) Characterization and biodistribution of recombinant and recombinant/ chimeric constructs of monoclonal antibody B72.3. Cancer Res. 49 (7), 1738–1745.
24. Beidler, C. B., Ludwig, J. R., Cardenas, J., Phelps, J., Pap-worth, C. G., Melcher, E., Sierzega, M., Myers, L. J., Unger, B. W., Fisher, M., et al. (1988) Cloning and high level expression of a chimeric antibody with specificity for human carci-noembryonic antigen. J. Immunol. 141 (11), 4053–4060.
25. Shaw, D. R., Khazaeli, M. B., and LoBuglio, A. F. (1988) Mouse/human chimeric antibodies to a tumor-associated antigen: Biologic activity of the four human IgG subclasses. JNCI, J. Natl. Cancer Inst. 80 (19), 1553–1559.
26. Steplewski, Z., Sun, L. K., Shearman, C. W., Ghrayeb, J., Daddona, P., and Loprowski, H. (1988) Biological activity of human-mouse IgGl, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. U.S.A. 85 (13), 4852–4856.
27. Sun, L. K., Curtis, P., Rakowicz-Szulczynska, E., Ghrayeb, J., Chang, N., Morrison, S. L., and Koprowski, H. (1987) Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17–1A. Proc. Natl. Acad. Sci. U.S.A. 84 (1), 214–218.
28. Shaw, D. R., Khazaeli, M. B., Sun, L. K., Ghrayeb, J., Daddona, P. E., McKinney, S., and LoBuglio, A. F. (1987) Characterization of a mouse/human chimeric monoclinal antibody (17–1A) to a colon cancer tumor-associated antigen. J. Immunol. 138 (12), 4534–4538.
29. Liu, A. Y., Robinson, R. R., Murray, E. D., Jr., Ledbetter, J. A., Hellstrom, I., and Hellstrom, K. E. (1987) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J. Immunol. 139 (10), 3521–3526.
30. Brown, B. A., Davis, G. L., Saltzaber-Muller, J., Simon, P., Ho, M. K., Shaw, P. S., Stone, B. A., Sands, H., and Moore, G. P. (1987) Tumor-specific genetically engineered murine/ human chimeric monoclonal antibody. Cancer Res. 47 (13), 3577–3583.
31. Sahagan, B. G., Dorai, H., Saltzgaber-Muller, J., Toneguzzo, F., Guindon, C. A., Lilly, S. P., McDonald, K. W., Morrissey, D. V., Stone, B. A., Davis, G. L., et al. (1986) A genetically engineered murine/ human chimeric antibody retains specificity for human tumor-associated antigen. J. Immunol. 137 (3), 1066–1074.
32. Boulianne, G. L., Hozumi, N., and Shulman, M. J. (1984) Production of functional chimaeric mouse/human antibody. Nature 312 (5995), 643–646.
33. Benecerraf, B. (1985) Significance and biological function of class II MHC molecules. Rous-Whipple Award lecture. Am. J. Pathol. 120 (3), 334–343.
34. Edelman, G. M., et al. (1969) Complete sequence of human IgGl. Proc. Natl. Acad. Sci. U.S.A. 63, 78.
35. Poljak, R. J. (1975) Three-dimensional structure, function and genetic control of immunoglobulin. Nature 256, 373.
36. Lit-man, G. W., Litman, R. S., Good, R. A., and Rosenberg, A. (1973) Molecular dissection of immunoglobulin G. Conformational interrelationships of te subunits of human immunoglobulin G. Biochemistry 12 (10), 2004–2011.
37. Mathur, A., Lynch, R. G., and Kohler, G. (1988) The contribution of constant region domains to the binding of murine IgM to Fc mu receptors on T cells. J. Immunol 140 (1), 143–147.
38. Dessein, A., Germain, R. N., Dorf, M. E., and Benacerraf, B. (1979) IgE responses of synthetic polypeptide antigens. I. Simultaneous Ir gene and isotype-spe-cific regulation of IgE responses to L-glutamic acid60-L-alanine30-L-tyrosinel0 (GAT). J. Immunol. 123 (1), 463–470.
39. Mendez, E., Frangione, B., and Franklin, E. C. (1973) Structure of immunoglobulin A. Amino acid sequence of cys-teine-containing peptides from the J chain. Biochemistry 12 (6), 1119–1124.
40. Wolfenstein-Todel, C., Prelli, F., Frangione, B., and Franklin, E. C. (1973) Immunoglobulin A. Arrangement of disulfide bridges in the “hinge” region of an immunoglobulin lin A-l human myeloma protein. Biochemistry 12 (25), 5195–5197.
41. Hurwitz, E., Wilchek, M., and Pitha, J. (1980) Soluble mac-romolecules as carriers for daunorubicin. J. Appl. Biochem. 2, 25–35.
42. Lamoyi, E. (1986) Preparation of F(ab’)2 fragments from mouse IgG of various subclasses. Methods Enzymol. 121, 652–663.
43. Parr, D. M., Connell, G. E., Kells, D. I., and Hofmann, T. (1976) Fb’2, a new peptic fragment of human immunoglobulin G. Biochem. J. 155 (1), 31–36.
44. Parr, D. M. (1977) Fragments produced by digestion of human immunoglobulin G subclasses with pepsin in urea. Bio -ehem. J. 165 (2), 303–308.
45. Bumol, T. F., Laguzza, B. C., Baker, A. L., Todd, G. C., Pohland, R. C., and Apelgren, L. D. (1988) Studies on 9.2.27-4-desacetyl vinblastine-3-carboxyhydrazide (9.2.27-DAVLB-hydrazide): Preclinical pharmacology and toxicology profiles for human melanoma therapy. Abstracts of Papers, Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 19.
46. McKearn, T. J., Lopes, A. D., Radcliffe, R. D., Coughlin, D. J., Hrubiec, R. T., and Rodwell, J. D. (1988) In vivo efficacy of site-specific anti-folate monoclonal antibody conjugates. Abstracts of Papers, Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 17.
47. Rowland, G. F., Simmonds, R. G., Corvalan, J. R. F., et al. (1983) Monoclonal antibodies for targeted therapy with vindesine. Protides Biol. Fluids 30, 375.
48. Johnson, I. S., Spearman, M. E., Todd, G. C., Zimmerman, J. L., and Bumol, T. F. (1987) Monoclonal antibody drug conjugates for site-directed cancer chemotherapy: Preclinical pharmacology and toxicology studies. Cancer Treat. Rev. 14 (3–4), 193–196.
49. Johnson, D. A. and Laguzza, B. C. (1987) Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D. Cancer Res. 47 (12), 3118–3122.
50. Johnson, I. S., Cullinan, G. J., Boder, G. B., Grindey, G. B., and Laguzza, B. C. (1987) Structural modifications of the vinca alkaloids. Cancer Treat. Rev. 14 (3–4), 407–410.
51. Blakey, D. C. and Thorpe, D. C. (1983) An overview of therapy with immunotoxins containing ricin or its A Chain. Antibody, Immunoconjugates, Radiopharm. 1, 1–16.
52. Vitetta, E. S. and Uhr, J. W. (1985) Immunotoxin. Annu. Rev. Immunol. 3, 197–212.
53. Pastan, I., Willingham, M. C., and FitzGerald, D. J. P. (1986) Immunotoxins. Cell 47, 641–648.
54. Laurent, G., Pris, J., and Farcet, J-P. (1986) Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood 67, 1680–1687.
55. Spitler, L., del Rio, M., Khentigan, A., et al. (1987) Therapy of patients with malignant melanoma using a monoclonal antimela-noma antibody ricin A chain immunotoxin. Cancer Res. 47, 1717–1723.
56. Thorpe, P. E., Wallace, P. M., Knowles, P. P., Reif, M. G., Brown, A. N., Watson, G. J., Knyba, R. E., Wawrzynczak, E. J. and Blakey, D. C. (1987) New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res. 47 (22), 5924–5931.
57. Worrell, N. R., Cumber, A. J., Parnell, G. D., Mirza, A., Forrester, J. A., and Ross, W. C. (1986) Effect of linkage variation of pharmacokinetics of ricin A chain-antibody conjugates in normal rats. Anticancer Drug Des. 1 (3), 179–188.
58. Senter, P. D., Saulnier, M. G., Schreiber, G. J., Hirschberg, D. L., Brown, J. P., Hellstrom, I., and Hellstrom, K. E. (1988) Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. U.S.A. 85, 4842–4846.
59. Yang, H. M. and Reisfeld, R. A. (1988) Pharmacokinetics and biodistribution of doxorubidin-monoclonal antibody 9.2.27 conjugate. Abstracts of Papers, Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 69.
60. 111In-labeled monoclonal antibody 96.5. Cancer Res. 45, 2376–2381.
61. Murray, J. L., Rosenblum, M. G., Lamki, L., et al. (1987) Clinical parameters related to optimal tumor localization of indium-lll-labeled mouse antimelanoma monoclonal antibody ZME-018. J. Nucl. Med. 28, 25–33.
62. Epenetos, A. A., Munro, A. J., Stewart, S. et al. (1987) Antibody-guided irradiation of advanced ovarian cancer with intraperi-toneally administered radiolabeled monoclonal antibodies. J. Clin. Oncol. 5, 1890–1899.
63. 131Lym-l Monoclonal antibody. Antibody, Immunoconjugates Radiopharm. 1, 17–33.
64. Adams, G. P., DeNardo, S. J., Deshpands, S. V., DeNardo, G. L., Meares, C. F., McCall, M. J., and Epstein, A. L. (1989) Effect of mass of 111ln-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice. Cancer Res. 49 (7), 1707–1711.
65. Meares, C. F., McCall, M. J., Desh-pande, S. V., DeNardo, S. J., and Goodwin, D. A. (1988) Chelate radiochemistry: Cleavable linkers lead to altered levels of radioactivity in the liver. Int. J. Cancer. 2, 99–102.
66. Cole, W. C., DeNardo, S. J., Meares, C. F., McCall, M. J., DeNardo, G. L., Epstein, A. L., O’Brien, H. A., and Moi, M. K. (1987) Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J. Nucl. Med. 28 (1), 83–90.
67. Haseman, M. K., Goodwin, D. A., Meares, C. F., Kaminski, M. S., Wensel, T. G., McCall, M. J., and Levy, R. (1986) Metabolizable 111 In chelate conjugated anti-idiotype monoclonal antibody for radio-immunodetection of lymphoma in mice. Eur. J. Nucl. Med. 12 (9), 455–460.
68. Meares, C. F. (1986) Chelating agents for the binding of metal ions to antibodies. Int. J. Radiat. Appl. Instrum. 13 (4), 311–318.
69. Goodwin, D. A., Meares, C. F., McTigue, M., McCall, M. J., and Chaovapong, W. (1986) Metal decomposition rates of 111 ln-DTPA and EDTA conjugates of monoclonal antibodies in vivo. Nucl. Med. Commun. 7 (11), 831–838.
70. Goodwin, D. A., Meares, C. F., David, G. F., McTigue, M., McCall, M. J., Frincke, J. M., Stone, M. R., Bartholomew, R. M., and Leung, J. P. (1986) Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Int. J. Radiat. Appl. Instrum. 13 (4), 383–391.
71. Reardan, D. T., Meares, C. F., Goodwin, D. A., McTigue, M., David, G. S., Stone, M. R., Leung, J. P., Bartholomew, R. M., and Frincke, J. M. (1985) Antibodies against metal chelates. Nature 316 (6025), 265–268.
72. Goodwin, D. A., Meares, C. F., DeRiemer, L. H., Diamanti, C. L., Goode, R. L., Baumert, J. E., Jr., Sartoris, D. J., Lantieri, R. L., and Fawcett, H. D. (1981) Clinical studies with In-111 BLEDTA, a tumor-imaging conjugate of bleomycin with a bifunctional chelating agent. J. Nucl. Med. 22 (9), 787–792.
73. Meares, C. F., McCall, M. J., Rear-dan, D. T., Goodwin, D. A., Diamanti, C. I., and McTigue M. (1984) Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem. 142 (1), 68–78.
74. Baker, R. J., Diamanti, C. I., Goodwin, D. A., and Meares, C. F. (1981) Technetium-99 m complexes of EDTA analogs: Studies of the radiochemistry and biodistribution. Int. J. Nucl. Med. Biol. 8 (2–3), 159–169.
75. 11lIn-labeled anti-CEA murine monoclonal antibody, ZCE025. Abstracts of Papers, Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 28.
76. 2 antibody fragment as a potential -radioimmunotherapy agent. Abstracts of Papers, Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 31.
77. King, T. P., Zhao, S. W., and Lam, T. (1986) Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry 25 (19), 5774–5779.
78. Offord, R. and Rose, K. (1987) European Patent Number 0243929.
79. Jones, R. M. and Offord, R. E. (1982) The proteinase-catalysed synthesis of peptide hydrazides. Biochem. J. 203 (1), 125–129.
80. Rose, K., DePury, H., and Offord, R. E. (1983) Rapid preparation of human insulin and insulin analogues in high yield by enzyme-assisted semi-synthesis. Biochem. J. 211 (3), 671–676.
81. Rose, K., Herrero, C., Proud-foot, A. E., Offord, R. E., and Wallace, C. J. (1988) Enzyme-assisted semisynthesis of polypeptide active esters and their use. Biochem. J. 249 (1), 83–88.
82. Coughlin, D. J., King, H. D., DeVirgilio, M., Greway, G., and Alvarez, V. (1989) Tumor localization of antitumor drug-antibody conjugates. Biodistribution of radiolabeled N,Ndimethyl adriamycin-B72.3 antibody conjugates with LS174T tumor xenografts in mice. Abstracts of Papers American Chemical Society Meeting, Dallas, Texas, Abstract No. 72, American Chemical Society, Washington, DC.
83. Barton, R., Starling, J., Hinson, A., Maciak, R., and Koppel, G. (1988) Adriamycin immunoconjugate designed to release free adriamycin from a linking moiety covalently bound to oxidized monoclonal antibody by reductive amination. Abstracts of Papers, Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 78.
84. Figures 11, 17, and 22 were presented as part of an invited lecture, see: Bumol, T. F. (1989) Chemoimmunoconjugates for site-directed therapy of human adenocarcinomas. Abstracts of Papers, Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 50.
85. Gorman, M., Neuss, N., and Cone, N. J. (1965) Vinca alkaloids. XVII. Chemistry of catharanthine. J. Am. Chem. Soc. 87 (1), 93–99.
86. Varki, N. M., Reisfeld, R. A., and Walker, L. E. (1984) Antigens associatd with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res. 44 (2), 681–687.
87. Strnad, J., Hamilton, A. E., Beavers, L. S., Gamboa, G. C., Apelgren, L. D., Taber, L. D., Sportsman, J. R. Bumol, T. F., Sharp, J. D., and Gadski, R. A. (1989) Molecular cloning and characterization of a human adenocarcinoma/ epithelial cell surface antigen complementary DNA. Cancer Res. 49 (2), 314–317.
88. Bumol, T. F., Marder, P., DeHerdt, S. V., Borowitz, M. J., and Apelgren, L. D. (1988) Characterization of the human tumor and normal tissue reactivity of the KS1/ 4 monoclonal antibody. Hybridoma 7 (4), 407–415.
89. Baker, A. L., Bumol, T. F., and Conrad, P. C. (1988) Heterogeneity of monoclonal antibodies; implications for immunoconjugate preparation. Abstracts of Papers, Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 93.
90. Ueyama, Y. (1987) Utilization of nude mice in research on human cancer-screening system of anticancer agent using human tumor xenografts in nude mice. Prog. Clin. Biol. Res. 229, 287–310.
91. Garrett, A. J. and Franks, C. R. (1976) Letter: Cancer xenografts in nude mice. Lancet 1 (7952), 195.
92. Schmidt, M. and Good, R. A. (1976) Letter: Cancer xenografts in nuce mice. Lancet 1 (7949), 39.
93. Fodstad, O., Aass, N., and Pihl, A. (1980) Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice. Int. J. Cancer 25 (4), 453–458.
94. Mattern, J., Bak, M., Hahn, E. W., and Volm, M. (1988) Human tumor xenografts as model for drug testing. Cancer Metastasis Reu. 7 (3), 263–284.
95. Taetle, R., Jones, O. W., Honeysett, J. M., Abram-son, L., Bradshaw, C., and Reid, S. (1987) Use of nude mouse xenografts as preclinical screens. Characterization of xenograft-derived melanoma cell lines. Cancer 60 (8), 1836–1841.
96. Taetle, R., Honeysett, J. M., Rosen, F., and Shoemaker, R. (1986) Use of nude mouse xenografts as preclinical drug screens. Further studies on in vitro growth of xenograft tumor colony-forming cells. Cancer 58 (9), 1969–1978.
97. Bumol, T. F., Baker, A. L., Andrews, E. L., DeHerdt, S. V., Briggs, S. L., Spearman, M. E., and Apelgren, L. D. (1988) Antibody Mediatd Delivery Systems (John D. Rod-well, Ed.) Marcel Dekker, Inc., New York, Basel.
98. Johnson, I. S., Spearman, M. E., Todd, G. C., Zimmerman, J. L., and Bumol, T. F. (1987) Monoclonal antibody drug conjugates for site-directed cancer chemotherapy: Preclinical pharmacology and toxicology studies. Cancer Treat. Rev. 14 (3–4), 193–196.
99. Bumol, T. F., personal communication. Tumor mass measurements did not vary over 30 % of the mean. Animals treated with KS1/4-DAVLB had tumor masses which were significantly different than control groups (P < O.001 via Student's t test analysis).
100. 3H]vinblastine to embryonic chick brain tubulin and tubulin from sea urchin sperm tail outer doublet microtubules. Biochemistry 14 (26), 5586–5592.
101. Wilson, L. (1975) Microtubules as drug receptors: Pharmacological properties of microtubule protein. Ann. N.Y. Acad. Sci. 253, 213–31.
102. Hans, F. O., Dickerson, R. M., Wilson, L., and Owellen, R. J. (1978) Differences in the binding properties of vinca alkaloids and colchicine to tubulin by varying protein sources and methodology. Biochem. Pharmacol. 27 (1), 71–76.
103. Spearman, M. E., Goodwin, R. M., Apelgren, L. D., and Bumol, T. F. (1987) Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. J. Pharmacol. Exp. Ther. 241 (2), 695–703.
104. Bumol, T. F., Parrish, H., DeHerdt, S. V., Spearman, M. E., Pohland, R., Borowitz, M. J., Briggs, S. L., Baker, A. L., Marder, P., and Apelgren, L. D. (1987) Immunological Approaches to the Diagnosis and Therapy of Breast Cancer (Roberto L. Ceriani, Ed.) Plenum Press, New York.
105. Schneck, D. W., Petersen, B., Zimmerman, J., Butler, F., Dugan, W. (1989) Phase I studies with a monoclonal antibody vinca conjugate (MC, KSl/4-DAVLB) in patients with adenocarcinoma. Abstracts of Papers, Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 58.
106. Zimmerman, J., Schneck, D. W., and Petersen, B. (1989) Treatment-related lesions observed in patients with adenocarcinoma administered single and multiple doses of a monoclonal antibody vinca conjugate (KS1/4-DAVLB). Abstracts of Papers, Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 169.
107. Laguzza, B. C., Nichols, C. L., Briggs, S. L., Cullinan, G. J., Johnson, D. A., Starling, J. J., Baker, A. L., Bumol, T. F., Corvalan, J. R. (1989) New antitumor monoclonal antibody-vinca conjugates LY203625 and related compounds: Design, preparation, and representative in vivo activity. J. Med. Chem. 32 (3), 548–555.
108. Springer, C. J., Antoniew, P., Bagshawe, K. D., Searle, F., Melton, R. G., and Sherwood, R. F. (1988) A novel approach to prodrug activation using a monoclonal antibody conjugated to carboxypeptidase G2. Abstracts of Papers, Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer p 43.